NCT04016753

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

The Effect of BMS-986256 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: Female
• Age: 21 Years – 40 Years
• Healthy volunteers: Accepted

Summary

A comparative study of BMS-986256 with a combined oral contraceptive in healthy female participants to determine the effectiveness when taken together

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	BMS-986256	30 mg(6ml)
DRUG	Loestrin	1.5 mg Norethindrone and 30ug ethinyl estradiol

Timeline

• Start date: 2019-08-05
• Primary completion: 2020-02-21
• Completion: 2020-02-21
• First posted: 2019-07-11
• Last updated: 2022-05-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study